C4IP Urges Senate Judiciary to Ignore Common Myths About Drug Patents
On May 20, the Council for Innovation Promotion (C4IP) sent a letter addressed to the U.S. Senate Committee on the Judiciary one day before the committee held a hearing on competition and consumer pricing in the prescription drug market.
Source: ipwatchdog.com